Collectively, the data demonstrate that adding either toripalimab, tislelizumab or camrelizumab to chemotherapy provides survival benefit in untreated recurrent or metastatic NPC, and the survival benefit of adding toripalimab or tislelizumab to chemotherapy appears to be independent of baseline PD-L1 expression level. Here, CD274 is linked to nasopharyngeal carcinoma.